You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.
What conditions do you have?
What conditions do you have?
This trial is testing the combination of two drugs to treat acute myeloid leukemia that has returned or not responded to treatment. The first drug, ruxolitinib, may stop cancer cell growth by blocking enzymes needed for cell growth. The second drug, venetoclax, is a BCL-2 inhibitor that may stop cancer cell growth by blocking a protein needed for cancer cell survival. This study is being done to see if the combination of these two drugs works better than standard of care chemotherapy.
This histogram enumerates side effects from a completed 2020 Phase 3 trial (NCT02038036) in the Best Available Therapy ARM group. Side effects include: Pruritus with 23%, Headache with 12%, Diarrhoea with 9%, Upper respiratory tract infection with 9%, Thrombocytopenia with 8%.
1 Treatment Group
Treatment (ruxolitinib, venetoclax)
1 of 1
31 Total Participants · 1 Treatment Group
Primary Treatment: Ruxolitinib · No Placebo Group · Phase 1
Treatment (ruxolitinib, venetoclax)Experimental Group · 2 Interventions: Ruxolitinib, Venetoclax · Intervention Types: Drug, Drug
Drug Approval Stage
How many patients have taken this drug
Screening: ~3 weeks
Reporting: from first pr or better to loss of best response, or date of last assessment (up to 24 months)
Who is running the clinical trial?
Brian DrukerLead Sponsor
Oregon Health and Science UniversityOTHER
885 Previous Clinical Trials
6,828,510 Total Patients Enrolled
6 Trials studying Leukemia, Myeloid
121 Patients Enrolled for Leukemia, Myeloid
822 Previous Clinical Trials
469,574 Total Patients Enrolled
39 Trials studying Leukemia, Myeloid
5,191 Patients Enrolled for Leukemia, Myeloid
Incyte CorporationIndustry Sponsor
309 Previous Clinical Trials
46,281 Total Patients Enrolled
5 Trials studying Leukemia, Myeloid
200 Patients Enrolled for Leukemia, Myeloid
Jennifer Saultz, MDPrincipal InvestigatorOHSU Knight Cancer Institute
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
Creatinine clearance is 30 mL/min or greater.
Total serum bilirubin =< 1.5 x ULN.
You are able to understand the nature and purpose of the study and are willing to sign a written informed consent document.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.